A study led by Northeastern University professor Jonathan Peelle with researchers from across the globe has confirmed that people's ability to detect background sounds varies from person to person ...

This presentation follows the recent Fast Track Designation granted by the U.S. FDA for EBC-129 in the treatment of PDAC patients.

EBC-129 is an antibody-drug conjugate (ADC) that selectively targets a novel, tumour-specific N-glycosylated epitope found on both CEACAM5 and CEACAM6. The expansion cohort for pancreatic ductal ...

Background: Breast cancer is among the most common malignancies globally, placing a substantial strain on healthcare systems and affecting patient populations significantly. Human epidermal growth ...

Presentation information: Title: Phase 2 dose expansion study of DSP107, a first-in-class bi-specific 4-1BB T-cell engager, with and without atezolizumab in metastatic MSS colorectal cancer patients.

Presentation Time: 2:09 PM - 2:21 PM CDT Location: McCormick Place, Hall B1 About Protagonist Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company.

Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025 NEWARK, CA / ACCESS Newswire / April 23, 2025 / Protagonist Therapeutics, Inc.

THE WOODLANDS, TX, April 03, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix” or the "Company”), a medical device company focused on advancing precision nerve-targeted ...

The study uses a simplified, theoretical model of a black hole, known as a planar black hole. Unlike typical black holes, which have a spherical shape, a planar black hole's boundary is a flat ...

Presentation of the VW ID.Every1 study: outlook on the entry-level model Two years before launch, VW presents a study of a small car with electric drive.

A study co-authored by Filippo Radicchi at Indiana University proposed a theoretical framework specifically designed for understanding complex higher-order networks. The work could lead to ...

aTyr Pharma Announces Presentation of Phase 3 EFZO-FIT™ Study Data and Real-World Evidence on Pulmonary Sarcoidosis at ATS 2025 Conference January 29, 2025 — 08:13 am EST ...